Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Filgotinib versus Placebo and Adalimumab in Biologic-naïve Psoriatic Arthritis
2019-001996-35Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (3 arms), sponsored by Gilead Sciences. Primary endpoint: ACR20 response at Week 12. Started Jan 2020; status: completed.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2019-001996-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001996-35.